

Merodis advised C3BS related to the EUR 9,5m investment from PMV.

July 5th 2013, Brussels, Belgium

Merodis is pleased to announce that it successfully advised Cardio3 BioSciences (C3BS) in having secured PMV's (Participatie Maatschappij Vlaanderen) investment of EUR 9,5m in the company. The funds will be used to co-finance the company's Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for its lead compound C-Cure®.

Dr Christian Homsy, CEO of Cardio3 BioSciences, said: "Merodis has been instrumental in getting an additional corner stone investor such as PMV on board. I am very pleased that since January 2013 Merodis worked on securing the participation of PMV that has now concluded into our successful IPO."

Belgian Biotechnology company Cardio3 BioSciences is a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases. The CHART-1 trial represents the world's first Phase III trial for a pre-programmed cellular therapy targeting heart failure and builds on the successful outcome of the Phase II trial of which the results were recently published in the Journal of the American College of Cardiology (JACC).

For more information, please contact:

Dirk Marckx, dma@merodis.com , +32 495 38 17 81

Thierry Hazevoets, tha@merodis.com , +32 495 58 68 98

About Merodis

We provide middle-market companies with a wide range of financial advisory services in support of mergers, acquisitions, divestitures, capital raising and corporate restructuring. For detailed information concerning the range of services offered, recent transactions and credentials, please consult www.merodis.com

If you no longer wish to receive this information, please send an email with subject "Unsubscribe" to info@merodis.com. If you want to be informed on new investment opportunities or get the latest news about Merodis, please click <http://www.merodis.com/contact.php?l2=1>